臨床研究支援事業

CSPOR《がん臨床研究支援事業》

Comprehensive Support Project for Oncology Research

成果一覧

乳癌

POTENT

Lancet Oncol . 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial Masakazu Toi , Shigeru Imoto , Takanori Ishida , Yoshinori Ito , Hiroji Iwata , Norikazu Masuda , Hirofumi Mukai , Shigehira Saji , Akira Shimizu , Takafumi Ikeda , Hironori Haga , Toshiaki Saeki , Kenjiro Aogi , Tomoharu Sugie , Takayuki Ueno , Takayuki Kinoshita , Yuichiro Kai , Masahiro Kitada , Yasuyuki Sato , Kenjiro Jimbo , Nobuaki Sato , Hiroshi Ishiguro , Masahiro Takada , Yasuo Ohashi , Shinji Ohno


肺癌

LC05 (JP-CLEAR)

Japanese Journal of Clinical Oncology, hyac032, Published: 22 March 2022

Article Navigation Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)(仲 剛:国立国際医療研究センター病院)

Japanese Journal of Clinical Oncology, Volume 49, Issue 6, June 2019, Pages 554–558,

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial) (臼井 一裕:NTT東日本関東病院)


肺癌

LC-02

ESMO Open Cancer Horizons. DOI: 10.1136/esmoopen-2017-000214 / Published 14 September 2017

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study (後藤 悌:国立がん研究センター中央病院)


肺癌

LC-01

Anticancer Research March 2017 vol. 37 no. 3 1507-1513

Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting (葉 清隆:国立がん研究センター東病院)



胃癌

REVIVE Study (GC-01)

ESMO-GI/2022年6月

Impact of Salvage Chemotherapy after Nivolumab Therapy (NIVO):A Sub-Study of REVIVE(松岡 宏:藤田医科大学病院)

日本胃癌学会/2022年3月4日

Efficacy of Salvage Chemotherapy (CTx) by Response to Prior Nivolumab (NIVO): A Sub-Study of REVIVE(川上 武志:静岡県立静岡がんセンター)

日本臨床腫瘍学会/2022年2月17日

REVIVE study: An Observational Study in Chemotherapy ( CTx ) after Nivolumab (NIVO) for Advanced Gastric Cancer (AGC)(坂本 康寛:大崎市民病院)

ASCO-GI/2022年1月21日

REVIVE study: A Prospective Observational Study in Chemotherapy (CTx) after Nivolumab (NIVO) Therapy for Advanced Gastric Cancer (AGC)(松島 知広:埼玉県立がんセンター)

Future Oncology, Volume 17, Issue 8 / Published online: 21 September 2020

REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer(成田 有季哉:愛知県がんセンター)

日本臨床腫瘍学会/2019年7月18日

Chemotherapy after progREssiVe dIsease of niVolumab (NIV) thErapy (REVIVE study)(成田 有季哉:愛知県がんセンター)

日本胃癌学会/2019年2月28日

Trial in Progress: Chemotherapy after progREssiVe dIsease of niVolumab thErapy (REVIVE study)(成田 有季哉:愛知県がんセンター)

ASCO-GI/2019年1月

REVIVE study: Prospective observational study of efficacy and safety in chemotherapy after progREssiVe dIsease of niVolumab (NIV) thErapy for metastatic gastric cancer (mGC) (成田 有季哉:愛知県がんセンター)


肝細胞癌

LENS-HCC

日本肝癌研究会/2022年5月13日

切除不能肝細胞癌に対するレンバチニブ投与によるコンバージョン⼿術 -多施設前向き研究LENS-HCC trial-  Multicenter, single-arm trial to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial(日髙 匡章:長崎大学)

ASCO-GI/2022年1月21日

Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial(多田 正晴:兵庫医科大学病院)

日本癌治療学会/2019年10月25日

Multicenter, single-arm trial of lenvatinib followed by surgical resection for initially unresectable hepatocellular carcinoma: LENS-HCC trial(市田 晃彦:東京大学医学部附属病院)


前立腺癌

URO 01(PROSAS-Study)

Japanese Journal of Clinical Oncology / 2021年11月

A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study(杉元幹史:香川大学医学部附属病院)